Adverse drug reactions in children reported by European consumers from 2007 to 2011
- 486 Downloads
Background Information about medicines safety in children is very limited. Consumer adverse drug reaction (ADR) reports can provide information about serious and unknown ADRs from medicine use in children. Objective To characterize ADRs in children reported by consumers in Europe from 2007 to 2011. Methods We analysed ADRs reported to the European ADR database, EudraVigilance (EV) for individuals from birth to 17 years. Data were characterized with respect to age and sex of the child, type of ADR (system organ class and preferred term), seriousness and suspected medicines (anatomical therapeutic chemical classification system level 1 and 5). Results In total, 240 ADR reports corresponding to 670 ADRs were identified. The relatively largest share of ADRs were reported for infants below 1 year followed by teenagers, and 60 % of all ADRs were reported for girls. The majority of ADRs reported were of the general type (20 %) and nervous system disorders (15 %). The largest share of serious ADRs was of the type nervous system disorders (17 % of all serious). Three cases of death were reported. Vaccines and anti-infectives for systemic use contributed to 30 % of ADRs, antineoplastic and immunomodulating agents for 23 % and sex hormones for 13 %. Conclusion Only few paediatric ADR consumer reports were found in EudraVigilance. Many of these ADRs were serious, and fatal cases were reported, however also nonserious reports were present. The findings indicate that consumer reports may be of value in paediatric ADR signal detection.
KeywordsAdverse drug reactions Children Consumers EudraVigilance Paediatrics Pharmacovigilance
The authors would like to thank the European Medicines Agency for providing data and MSc Jesper Frederiksen and MSc Michael Due Larsen for assistance with data handling.
No external sources of funding were used to assist in the preparation of this study.
Conflicts of interest
The authors have no conflicts of interest to declare.
- 4.Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxytone. Int J Risk Saf Med. 2004;16:5–19.Google Scholar
- 8.Volume 9. Pharmacovigilance: medicinal products for human use and veterinary products. Available at http://ec.europa.eu/health/documents/eudralex/vol-9/index_en.htm (last accessed 14 July 2013).
- 9.European Medicines Agency. EudraVigilance access policy for medicines for human use. EMA/759287/2009 corr. Published 23 August 2011.Google Scholar
- 10.Official journal of the European communities. Regulation (EC) No. 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents. L 145/43.Google Scholar
- 11.MedDRA. Available at http://www.meddramsso.com (last accessed 14 July 2013).
- 12.WHO collaboration centre for drug statistics methodology (2007) Available at http://www.whocc.no/atc_ddd_index/ (last accessed 14 July 2013).